Additionally, FTO has been found to promote leukemia oncogene-mediated cell transformation and leukemia development, while inhibiting all-trans retinoic acid-induced differentiation of AML cells and regulating the expression of its target genes, such as ankyrin repeat and SOCS box-containing 2 (ASB2) and retinoic acid receptor alpha (RARA), through lowering m6A levels in mRNA transcripts (Li Z. et al., 2017). The gene discussed is ASB2; the disease is acute myeloid leukemia.